aid: oncoc4
name: OncoC4
description: 'OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical
  company headquartered in Rockville, Maryland, founded in 2020, with subsidiaries
  in Nanjing, Guangzhou and Beijing, China, and Brisbane, Australia. The company discovers
  and develops novel biologics for the treatment of cancer, working across immune
  checkpoints including CTLA-4, CD24, PD-1/VEGF and the Siglec family, with monoclonal
  antibodies, bispecific antibodies, antibody-drug conjugates and CAR T-cell therapies.
  Its lead clinical candidate is gotistobart (BNT316/ONC-392), a next-generation
  anti-CTLA-4 antibody co-developed and commercialized with BioNTech under a strategic
  collaboration announced in March 2023. OncoC4 publishes no developer program, public
  API, SDK or developer documentation; its corporate website runs on the Umbraco CMS,
  which serves a default OpenID Connect / OAuth 2.0 discovery document and JWKS for
  CMS member authentication.'
image: https://oncoc4.com/media/tlofbavh/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/oncoc4/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Oncology
- Immunotherapy
- Clinical Trials
- Healthcare
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/oncoc4-domain-security.yml
- type: WellKnown
  url: well-known/oncoc4-well-known.yml
- type: Authentication
  url: authentication/oncoc4-authentication.yml
- type: OAuthScopes
  url: scopes/oncoc4-scopes.yml
- type: Conformance
  url: conformance/oncoc4-conformance.yml
- type: LLMsTxt
  url: llms/oncoc4-llms.txt
- type: Website
  url: https://oncoc4.com/en/
- type: About
  url: https://oncoc4.com/en/about-us/
- type: Contact
  url: https://oncoc4.com/en/contact/
- type: PrivacyPolicy
  url: https://oncoc4.com/en/privacy-policy/
- type: Careers
  url: https://oncoc4.com/en/careers/
- type: News
  url: https://oncoc4.com/en/news-resources/news/
- type: LinkedIn
  url: https://www.linkedin.com/company/oncoc4
- type: SecondaryMarket
  url: https://forgeglobal.com/oncoc4_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 9
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    OncoC4 is a late clinical-stage biopharmaceutical company whose product is a
    drug, not software — the entire oncoc4.com site is an Umbraco-hosted corporate
    brochure (about, pipeline, clinical trials, publications, careers) with no
    developer section, and the only machine-readable documents it serves are
    Umbraco's default OIDC/OAuth member-login discovery files.
  evidence:
  - url: https://oncoc4.com/openapi.json
    status: 404
  - url: https://oncoc4.com/api-docs
    status: 404
  - url: https://oncoc4.com/graphql
    status: 404
  - url: https://oncoc4.com/.well-known/agent-card.json
    status: 404
  - url: https://oncoc4.com/.well-known/openid-configuration
    status: 200
  checked: '2026-08-04'